Is enasidenib officially included in the medical insurance directory?

Enasidenib has not yet been officially included in my country’s medical insurance catalog. This is mainly because the original drug of ensidipine has not yet been officially launched in the domestic market, resulting in the medical insurance system not covering the drug. If patients need to use ensidipine, they can only purchase it through formal overseas channels and cannot enjoy the medical insurance reimbursement policy. Therefore, the treatment costs must be borne by the patient themselves.

In overseas markets, the price of ensidipine is relatively high. Taking common specifications 50mg 30 tablets and 100mg 30 tablets as examples, the original drug may be sold for more than 300,000 yuan per box, and the specific price will change due to exchange rate fluctuations. The high cost makes it unaffordable for some patients, which has also become an important factor limiting its widespread use.

However, in response to the price issue, generic versions of ensidipine have also appeared in overseas markets, and the prices of these generic drugs are more affordable. For example, the generic ensidipine drug produced by Lucius Pharmaceutical Factory in Laos is 50mg*30 tablets, and the price is about more than 1,000 yuan. Although the price has been significantly reduced, its medicinal ingredients are basically the same as those of foreign original drugs, which can provide patients with a more economical treatment option.

In short, although ensidipine has not been included in domestic medical insurance and the price of the original drug is relatively high, the emergence of generic drugs has provided patients with more feasible medication options. If ensidipine can enter the domestic market and be included in medical insurance in the future, it will greatly ease the financial burden on patients and promote the clinical application of this type of targeted drugs.

Reference materials:https://www.idhifa.com/